Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) Stock Competitors & Peer Comparison

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, VRTX has a market cap of 138.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while VRTX trades at $547.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas VRTX's P/E ratio is 28.75. In terms of profitability, ARWR's ROE is -0.61%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, ARWR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check VRTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MRNA has a market cap of 100.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MRNA trades at $248.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MRNA's P/E ratio is -30.51. In terms of profitability, ARWR's ROE is -0.61%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, ARWR is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check MRNA's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, REGN has a market cap of 99.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while REGN trades at $959.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas REGN's P/E ratio is 21.03. In terms of profitability, ARWR's ROE is -0.61%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ARWR is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check REGN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARWR's ROE is -0.61%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ARWR is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check VRNA's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ARGX has a market cap of 60.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ARGX trades at $977.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ARGX's P/E ratio is 35.25. In terms of profitability, ARWR's ROE is -0.61%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, ARWR is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ARGX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ONC has a market cap of 44.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ONC trades at $419.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ONC's P/E ratio is 73.94. In terms of profitability, ARWR's ROE is -0.61%, compared to ONC's ROE of +0.18%. Regarding short-term risk, ARWR is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ONC's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARWR's ROE is -0.61%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARWR is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check SGEN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RVMD has a market cap of 39.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RVMD trades at $180.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RVMD's P/E ratio is -20.49. In terms of profitability, ARWR's ROE is -0.61%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, ARWR is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check RVMD's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RVMDW has a market cap of 37B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RVMDW trades at $8.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RVMDW's P/E ratio is -0.98. In terms of profitability, ARWR's ROE is -0.61%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, ARWR is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check RVMDW's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, GMAB has a market cap of 33.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while GMAB trades at $53.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas GMAB's P/E ratio is 40.60. In terms of profitability, ARWR's ROE is -0.61%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, ARWR is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check GMAB's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ROIV has a market cap of 30.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ROIV trades at $41.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ROIV's P/E ratio is -39.81. In terms of profitability, ARWR's ROE is -0.61%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, ARWR is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ROIV's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, INSM has a market cap of 26.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while INSM trades at $120.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas INSM's P/E ratio is -42.82. In terms of profitability, ARWR's ROE is -0.61%, compared to INSM's ROE of -0.83%. Regarding short-term risk, ARWR is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check INSM's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, UTHR has a market cap of 25.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while UTHR trades at $595.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas UTHR's P/E ratio is 21.30. In terms of profitability, ARWR's ROE is -0.61%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ARWR is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check UTHR's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, INCY has a market cap of 24.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while INCY trades at $122.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas INCY's P/E ratio is 16.43. In terms of profitability, ARWR's ROE is -0.61%, compared to INCY's ROE of +0.07%. Regarding short-term risk, ARWR is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check INCY's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while BNTX trades at $87.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas BNTX's P/E ratio is -11.37. In terms of profitability, ARWR's ROE is -0.61%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, ARWR is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check BNTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ALNY has a market cap of 21.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ALNY trades at $159.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ALNY's P/E ratio is 8.07. In terms of profitability, ARWR's ROE is -0.61%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, ARWR is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check ALNY's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARWR's ROE is -0.61%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, ARWR is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check BGNE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARWR's ROE is -0.61%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ARWR is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check DNA-WT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, EXEL has a market cap of 17.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while EXEL trades at $70.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas EXEL's P/E ratio is 20.20. In terms of profitability, ARWR's ROE is -0.61%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, ARWR is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check EXEL's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while NBIX trades at $174.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas NBIX's P/E ratio is 25.20. In terms of profitability, ARWR's ROE is -0.61%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, ARWR is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check NBIX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ASND has a market cap of 17.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ASND trades at $259.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ASND's P/E ratio is -107.14. In terms of profitability, ARWR's ROE is -0.61%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ARWR is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ASND's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while JAZZ trades at $248.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas JAZZ's P/E ratio is 9.26. In terms of profitability, ARWR's ROE is -0.61%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, ARWR is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check JAZZ's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, BBIO has a market cap of 15.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while BBIO trades at $79.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas BBIO's P/E ratio is -26.16. In terms of profitability, ARWR's ROE is -0.61%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, ARWR is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check BBIO's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, SMMT has a market cap of 13.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while SMMT trades at $16.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas SMMT's P/E ratio is -14.86. In terms of profitability, ARWR's ROE is -0.61%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, ARWR is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check SMMT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARWR's ROE is -0.61%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARWR is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check KRTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, HALO has a market cap of 11.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while HALO trades at $101.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas HALO's P/E ratio is 18.97. In terms of profitability, ARWR's ROE is -0.61%, compared to HALO's ROE of +5.44%. Regarding short-term risk, ARWR is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check HALO's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, KYMR has a market cap of 11.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while KYMR trades at $134.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas KYMR's P/E ratio is -37.25. In terms of profitability, ARWR's ROE is -0.61%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ARWR is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check KYMR's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TECH trades at $72.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TECH's P/E ratio is 37.53. In terms of profitability, ARWR's ROE is -0.61%, compared to TECH's ROE of +0.08%. Regarding short-term risk, ARWR is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check TECH's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while BMRN trades at $58.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas BMRN's P/E ratio is 28.04. In terms of profitability, ARWR's ROE is -0.61%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, ARWR is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check BMRN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARWR's ROE is -0.61%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ARWR is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check RNAM's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, PCVX has a market cap of 10.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while PCVX trades at $68.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas PCVX's P/E ratio is -8.99. In terms of profitability, ARWR's ROE is -0.61%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, ARWR is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check PCVX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, SYRE has a market cap of 10.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while SYRE trades at $106.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas SYRE's P/E ratio is -54.78. In terms of profitability, ARWR's ROE is -0.61%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, ARWR is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check SYRE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TGTX has a market cap of 10.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TGTX trades at $65.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TGTX's P/E ratio is 23.83. In terms of profitability, ARWR's ROE is -0.61%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, ARWR is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check TGTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MDGL trades at $433.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MDGL's P/E ratio is -33.83. In terms of profitability, ARWR's ROE is -0.61%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, ARWR is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check MDGL's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, PRAX has a market cap of 9.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while PRAX trades at $346.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas PRAX's P/E ratio is -26.78. In terms of profitability, ARWR's ROE is -0.61%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, ARWR is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check PRAX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARWR's ROE is -0.61%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARWR is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check RXDX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while KRYS trades at $308.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas KRYS's P/E ratio is 38.70. In terms of profitability, ARWR's ROE is -0.61%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, ARWR is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check KRYS's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARWR's ROE is -0.61%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARWR is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check NUVL's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ARWR's ROE is -0.61%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARWR is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CRNX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while PTGX trades at $134.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas PTGX's P/E ratio is 130.93. In terms of profitability, ARWR's ROE is -0.61%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, ARWR is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check PTGX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARWR's ROE is -0.61%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARWR is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check IMGN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas APGE's P/E ratio is -31.19. In terms of profitability, ARWR's ROE is -0.61%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ARWR is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check APGE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARWR's ROE is -0.61%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARWR is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check BPMC's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARWR's ROE is -0.61%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARWR is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CERE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CYTK trades at $58.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CYTK's P/E ratio is -8.11. In terms of profitability, ARWR's ROE is -0.61%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, ARWR is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check CYTK's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TWST has a market cap of 8.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TWST trades at $122.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TWST's P/E ratio is -55.22. In terms of profitability, ARWR's ROE is -0.61%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ARWR is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check TWST's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ABVX trades at $91.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ABVX's P/E ratio is -14.98. In terms of profitability, ARWR's ROE is -0.61%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ARWR is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ABVX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, AXSM has a market cap of 7.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while AXSM trades at $149.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas AXSM's P/E ratio is -38.97. In terms of profitability, ARWR's ROE is -0.61%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, ARWR is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check AXSM's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RYTM trades at $112.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RYTM's P/E ratio is -36.05. In terms of profitability, ARWR's ROE is -0.61%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, ARWR is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check RYTM's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while IMVT trades at $37.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas IMVT's P/E ratio is -13.13. In terms of profitability, ARWR's ROE is -0.61%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, ARWR is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check IMVT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TXG has a market cap of 7.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TXG trades at $62.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TXG's P/E ratio is -105.17. In terms of profitability, ARWR's ROE is -0.61%, compared to TXG's ROE of -0.08%. Regarding short-term risk, ARWR is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check TXG's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARWR's ROE is -0.61%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ARWR is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check MTSR's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, IBRX has a market cap of 7.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while IBRX trades at $6.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas IBRX's P/E ratio is -6.88. In terms of profitability, ARWR's ROE is -0.61%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, ARWR is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check IBRX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ORKA trades at $107.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ORKA's P/E ratio is -55.24. In terms of profitability, ARWR's ROE is -0.61%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, ARWR is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check ORKA's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CAI trades at $24.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CAI's P/E ratio is 68.64. In terms of profitability, ARWR's ROE is -0.61%, compared to CAI's ROE of +0.16%. Regarding short-term risk, ARWR is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check CAI's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, KOD has a market cap of 6.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while KOD trades at $109.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas KOD's P/E ratio is -26.22. In terms of profitability, ARWR's ROE is -0.61%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ARWR is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check KOD's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARWR's ROE is -0.61%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ARWR is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check MRUS's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARWR's ROE is -0.61%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ARWR is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ACLX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARWR's ROE is -0.61%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARWR is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check RETA's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MANE has a market cap of 6.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MANE trades at $156.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MANE's P/E ratio is -49.73. In terms of profitability, ARWR's ROE is -0.61%, compared to MANE's ROE of -0.20%. Regarding short-term risk, ARWR is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check MANE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CGON trades at $72.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CGON's P/E ratio is -26.99. In terms of profitability, ARWR's ROE is -0.61%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ARWR is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CGON's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while LGND trades at $316.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas LGND's P/E ratio is 34.78. In terms of profitability, ARWR's ROE is -0.61%, compared to LGND's ROE of +0.05%. Regarding short-term risk, ARWR is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check LGND's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while BLTE trades at $155.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas BLTE's P/E ratio is -83.39. In terms of profitability, ARWR's ROE is -0.61%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ARWR is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check BLTE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARWR's ROE is -0.61%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARWR is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CNTA's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MIRM trades at $94.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MIRM's P/E ratio is -6.50. In terms of profitability, ARWR's ROE is -0.61%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, ARWR is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check MIRM's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARWR's ROE is -0.61%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ARWR is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check TERN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ERAS trades at $16.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ERAS's P/E ratio is -18.06. In terms of profitability, ARWR's ROE is -0.61%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ARWR is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check ERAS's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while SRRK trades at $46.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas SRRK's P/E ratio is -13.51. In terms of profitability, ARWR's ROE is -0.61%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, ARWR is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check SRRK's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARWR's ROE is -0.61%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ARWR is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CDTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARWR's ROE is -0.61%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARWR is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ABCM's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARWR's ROE is -0.61%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARWR is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ISEE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while PTCT trades at $64.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas PTCT's P/E ratio is -46.36. In terms of profitability, ARWR's ROE is -0.61%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, ARWR is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check PTCT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARWR's ROE is -0.61%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARWR is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check APLS's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, EWTX has a market cap of 5.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while EWTX trades at $47.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas EWTX's P/E ratio is -25.71. In terms of profitability, ARWR's ROE is -0.61%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, ARWR is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check EWTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while COGT trades at $29.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas COGT's P/E ratio is -13.93. In terms of profitability, ARWR's ROE is -0.61%, compared to COGT's ROE of -0.71%. Regarding short-term risk, ARWR is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check COGT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while DNTH trades at $89.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas DNTH's P/E ratio is -21.52. In terms of profitability, ARWR's ROE is -0.61%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ARWR is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check DNTH's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TVTX trades at $52.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TVTX's P/E ratio is -115.64. In terms of profitability, ARWR's ROE is -0.61%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, ARWR is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check TVTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ADPT has a market cap of 4.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ADPT trades at $29.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ADPT's P/E ratio is -73.02. In terms of profitability, ARWR's ROE is -0.61%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, ARWR is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check ADPT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, IONS has a market cap of 4.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while IONS trades at $28.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas IONS's P/E ratio is -8.66. In terms of profitability, ARWR's ROE is -0.61%, compared to IONS's ROE of -1.20%. Regarding short-term risk, ARWR is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check IONS's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while DFTX trades at $34.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARWR's ROE is -0.61%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, ARWR is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check DFTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARWR's ROE is -0.61%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ARWR is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check FOLD's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARWR's ROE is -0.61%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ARWR is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check AKRO's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARWR's ROE is -0.61%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARWR is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ALPN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CRSP has a market cap of 4.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CRSP trades at $45.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CRSP's P/E ratio is -9.61. In terms of profitability, ARWR's ROE is -0.61%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, ARWR is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CRSP's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RLAY trades at $19.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RLAY's P/E ratio is -12.56. In terms of profitability, ARWR's ROE is -0.61%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, ARWR is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check RLAY's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TNGX trades at $25.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TNGX's P/E ratio is -31.00. In terms of profitability, ARWR's ROE is -0.61%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, ARWR is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check TNGX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARWR's ROE is -0.61%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARWR is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check OPT's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARWR's ROE is -0.61%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARWR is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check PRTC's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while XENE trades at $42.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas XENE's P/E ratio is -8.96. In terms of profitability, ARWR's ROE is -0.61%, compared to XENE's ROE of -0.40%. Regarding short-term risk, ARWR is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check XENE's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARWR's ROE is -0.61%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARWR is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check MRTX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, AMLX has a market cap of 4.1B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while AMLX trades at $31.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas AMLX's P/E ratio is -21.20. In terms of profitability, ARWR's ROE is -0.61%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, ARWR is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check AMLX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ABCL trades at $11.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ABCL's P/E ratio is -22.13. In terms of profitability, ARWR's ROE is -0.61%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, ARWR is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check ABCL's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ARWR's ROE is -0.61%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARWR is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CPRX's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, TARS has a market cap of 3.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while TARS trades at $76.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas TARS's P/E ratio is -70.42. In terms of profitability, ARWR's ROE is -0.61%, compared to TARS's ROE of -2.46%. Regarding short-term risk, ARWR is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for ARWR.Check TARS's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while ELVN trades at $51.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas ELVN's P/E ratio is -30.65. In terms of profitability, ARWR's ROE is -0.61%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, ARWR is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check ELVN's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARWR's ROE is -0.61%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARWR is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check RYZB's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, IOVA has a market cap of 3.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while IOVA trades at $8.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas IOVA's P/E ratio is -11.08. In terms of profitability, ARWR's ROE is -0.61%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, ARWR is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check IOVA's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARWR's ROE is -0.61%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARWR is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check CBAY's competition here

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARWR stands at 7B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, ARWR is priced at $49.36 on the NASDAQ, while VKTX trades at $28.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARWR currently has a P/E ratio of -21.94, whereas VKTX's P/E ratio is -5.27. In terms of profitability, ARWR's ROE is -0.61%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, ARWR is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for ARWR.Check VKTX's competition here